Risultati di ricerca
30 lug 2024 · Using Spectra™, a proprietary network medicine platform, Scipher commercializes tests revealing a person’s unique molecular disease signature and match it to the most effective therapy, ensuring optimal treatment from day one.
2 giorni fa · August 13, 2024. Cipher Pharmaceuticals ( TSE:CPH - Get Free Report) NASDAQ: CPHR was upgraded by research analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating in a note issued to investors on Tuesday, BayStreet.CA reports. The brokerage presently has a C$16.00 price target on the stock, up from their prior price target of C$9.50.
3 giorni fa · It’s possible that by utilising its newly acquired U.S. based sales force, which has relationships with dermatologists, Cipher may be able to raise awareness among prescribers, pharmacists and patients of Natroba’s efficacy as a scabies treatment option.
31 lug 2024 · One of the main differences between caput succedaneum and cephalohematoma is the location of the swelling in relation to the periosteum, the membrane covering the baby’s skull. In caput succedaneum, swelling occurs above the periosteum. In a cephalohematoma, the bleeding occurs below the periosteum.
7 ago 2024 · Cipher Pharma’s acquisition of ParaPRO’s Natroba assets and operations have transformed the company from a conservatively financed melting ice cube with a call option on a promising but speculative toenail fungus treatment, to a moderately leveraged growth company with many avenues to deploy capital profitably, of which the ...
19 lug 2024 · Purpose: To assess the safety and efficacy of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib as neoadjuvant therapy in patients with surgically resectable stage I-IIIA EGFR -mutated non-small cell lung cancer (NSCLC).
6 ago 2024 · It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead ...
